Identification of soluble and membrane-bound isoforms of porcine tumor necrosis factor receptor 2

Xenotransplantation

Volumn 18, Issue 2, 2011, Pages 131-146

  Uribe Herranz, Mireia ^a   Casinghino, Sandra R ^b,c   Bosch Presegué, Laia ^a   Fodor, William L ^b,c   Costa, Cristina ^a,b,d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b ALEXION PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

cytokine; endothelium; tumor necrosis factor; tumor necrosis factor R2; Xenotransplantation

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; ENDOTHELIUM CELL; EXON; GENE AMPLIFICATION; GRAFT REJECTION; HUMAN; IMMUNOCOMPETENT CELL; LUNG; MEMBRANE BINDING; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; SWINE;

AMINO ACID SEQUENCE; ANIMALS; CELL MEMBRANE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HUMANS; KIDNEY; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, MESSENGER; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 79955040833     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2011.00634.x     Document Type: Article

References (53)

1. Bradley JR,. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149-160. (Pubitemid 351160153)
2. Kim EY, Priatel JJ, Teh S, Teh H,. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 2006; 176: 1026-1035. (Pubitemid 43099703)
3. Chen X, Oppenheim JJ,. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun 2010; 11: 119-134.
4. Chandrasekharan UM, Siemionow M, Unsal M, et al., Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo. Blood 2007; 109: 1938-1944. (Pubitemid 46348190)
5. Luo D, Luo Y, He Y, et al., Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am J Pathol 2006; 169: 1886-1898. (Pubitemid 351182017)
6. Pan S, An P, Zhang R, et al., Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002; 22: 7512-7523.
7. Bodmer J, Schneider P, Tschopp J,. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19-26. (Pubitemid 34131621)
8. Chan FK, Chun HJ, Zheng L, et al., A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-2354. (Pubitemid 30448156)
9. Grell M, Douni E, Wajant H, et al., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
10. Grell M, Wajant H, Zimmermann G, Scheurich P,. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998; 95: 570-575. (Pubitemid 28083784)
11. Higuchi M, Aggarwal BB,. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 1994; 152: 3550-3558. (Pubitemid 24098052)
12. Wilson NS, Dixit V, Ashkenazi A,. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 348-355.
13. Rauert H, Wicovsky A, Müller N, et al., Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem 2010; 285: 7394-7404.
14. Al-Lamki RS, Wang J, Vandenabeele P, et al., TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005; 19: 1637-1645. (Pubitemid 41429521)
15. Weiss T, Grell M, Siemienski K, et al., TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol 1998; 161: 3136-3142. (Pubitemid 28425742)
16. Li X, Yang Y, Ashwell JD,. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002; 416: 345-347.
17. Grell M, Zimmermann G, Gottfried E, et al., Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999; 18: 3034-3043. (Pubitemid 29255612)
18. Lainez B, Fernandez-Real JM, Romero X, et al., Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol 2004; 16: 169-177. (Pubitemid 38054638)
19. Seitz C, Muller P, Krieg RC, Mannel DN, Hehlgans T,. A novel p75TNF receptor isoform mediating NFkappa B activation. J Biol Chem 2001; 276: 19390-19395.
20. Scherübl C, Schneider-Brachert W, Schütze S, Hehlgans T, Männel DN,. Colocalization of endogenous TNF with a functional intracellular splice form of human TNF receptor type 2. J Inflamm 2005; 2: 7.
21. Eason JD, Wee S, Kawai T, et al., Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1995; 59: 300-305.
22. Or R, Kalinkovich A, Nagler A, et al., Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications. Cytokines Mol Ther 1996; 2: 243-250. (Pubitemid 27065038)
23. Brown GR, Lee E, Thiele DL,. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J - >C57BL/6J x bm12)F1 mice. J Immunol 2002; 168: 3065-3071. (Pubitemid 34211689)
24. Diller R, Winde G, Kötting S, et al., sTNF-RII: is it useful for the early diagnosis of rejection and for prognosis after renal transplantation? Transpl Int 2002; 15: 335-340. (Pubitemid 36068186)
25. Al-Lamki RS, Brookes AP, Wang J, et al., TNF receptors differentially signal and are differentially expressed and regulated in the human heart. Am J Transplant 2009; 9: 2679-2696.
26. Lin Y, Vandeputte M, Waer M,. Contribution of activated macrophages to the process of delayed xenograft rejection. Transplantation 1997; 64: 1677-1683. (Pubitemid 28041699)
27. Lin H, Gastman BR, Wei RQ, et al., Phase-directed therapy and cardiac xenograft survival. J Surg Res 1997; 72: 84-88. (Pubitemid 27446640)
28. Carel JC, Sheehan KC, Schreiber RD, Lacy PE,. Prevention of rejection of transforming growth factor beta-treated rat-to-mouse islet xenografts by monoclonal antibody to tumor necrosis factor. Transplantation 1993; 55: 456-458. (Pubitemid 23065497)
29. Chen C, Kuehn C, Bretzel RG, Linn T,. Anti-inflammatory thalidomide improves islet grafts survival and functions in a xenogenic environment. PLoS ONE 2009; 4: e6312.
30. Kirkiles-Smith NC, Tereb DA, Kim RW, et al., Human TNF can induce nonspecific inflammatory and human immune-mediated microvascular injury of pig skin xenografts in immunodeficient mouse hosts. J Immunol 2000; 164: 6601-6609. (Pubitemid 30408847)
31. Jorgensen C, Apparailly F, Couret I, et al., Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology 1998; 93: 518-523. (Pubitemid 28172624)
32. Sommaggio R, Máñez R, Costa C,. TNF, pig CD86, and VCAM-1 identified as potential targets for intervention in xenotransplantation of pig chondrocytes. Cell Transplant 2009; 18: 1381-1393.
33. Kobayashi T, Taniguchi S, Neethling FA, et al., Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 1997; 64: 1255-1261. (Pubitemid 27495957)
34. Ashton-Chess J, Roussel JC, Manez R, et al., Cellular participation in delayed xenograft rejection of hCD55 transgenic pig hearts by baboons. Xenotransplantation 2003; 10: 446-453. (Pubitemid 37129889)
35. Manna PP, Duffy B, Olack B, Lowell J, Mohanakumar T,. Activation of human dendritic cells by porcine aortic endothelial cells: transactivation of naïve T cells through costimulation and cytokine generation. Transplantation 2001; 72: 1563-1571. (Pubitemid 33095516)
36. Kim TJ, Kim N, Kim EO, et al., Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology 2010; 130: 545-555.
37. Hetherington VJ, Kawalec JS, Dockery DS, et al., Immunologic testing of xeno-derived osteochondral grafts using peripheral blood mononuclear cells from healthy human donors. BMC Musculoskelet Disord 2005; 6: 36.
38. Lindeborg E, Kumagai-Braesch M, Möller E,. Phenotypic and functional characterization of human T cell clones indirectly activated against adult pig islet cells. Xenotransplantation 2006; 13: 41-52.
39. Batten P, Yacoub MH, Rose ML,. Effect of human cytokines (IFN-gamma, TNF-alpha, IL-1 beta, IL-4) on porcine endothelial cells: induction of MHC and adhesion molecules and functional significance of these changes. Immunology 1996; 87: 127-133. (Pubitemid 26029490)
40. Costa C, Bell NK, Stabel TJ, Fodor WL,. Use of porcine tumor necrosis factor receptor 1-Ig fusion protein to prolong xenograft survival. Xenotransplantation 2004; 11: 491-502. (Pubitemid 39423071)
41. Daniel S, Arvelo MB, Patel VI, et al., A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 2004; 104: 2376-2384. (Pubitemid 39331836)
42. Horvath-Arcidiacono JA, Porter CM, Bloom ET,. Human NK cells can lyse porcine endothelial cells independent of their expression of Galα(1,3)-Gal and killing is enhanced by activation of either effector or target cells. Xenotransplantation 2006; 13: 318-327. (Pubitemid 43884466)
43. Costa C, Casinghino SR, Fodor WL,. Characterization of porcine tumor necrosis factor receptor 2: implications for xenotransplantation. Transplant Proc 2007; 39: 2443-2446. (Pubitemid 47418223)
44. Costa C, Brokaw JL, Wang Y, Fodor WL,. Delayed rejection of porcine cartilage is averted by transgenic expression of α1,2-fucosyltransferase. FASEB J 2003; 17: 109-111.
45. Selden RF,. Analysis of RNA by Northern hybridization. In:, Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current protocols in Molecular Biology. New York: Greene Publishing Associates, 1992: 4.9.1-4.9.8.
46. Sarrias MR, Padilla O, Monreal Y, et al., Biochemical characterization of recombinant and circulating human Sp alpha. Tissue Antigens 2004; 63: 335-344. (Pubitemid 38406694)
47. Hauser A, Hehlgans T, Männel DN,. Characterization of TNF receptor type 2 isoform in the mouse. Mol Immunol 2007; 44: 3563-3570. (Pubitemid 46754447)
48. Goodwin RG, Anderson D, Jerzy R, et al., Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol Cell Biol 1991; 11: 3020-3026. (Pubitemid 21895687)
49. Ware CF, Crowe PD, Vanarsdale TL, et al., Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol 1991; 147: 4229-4238.
50. Clancy L, Mruk K, Archer K, et al., Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-18104. (Pubitemid 41798508)
51. Lewis M, Tartaglia LA, Lee A, et al., Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991; 88: 2830-2834. (Pubitemid 21916513)
52. Oropeza M, Petersen B, Carnwath JW, et al., Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli. Xenotransplantation 2009; 16: 522-534.
53. Klymiuk N, Aigner B, Brem G, Wolf E,. Genetic modification of pigs as organ donors for xenotransplantation. Mol Reprod Dev 2010; 77: 209-221.